Why Attend
Animal Health Innovation Asia is a premier B2B conference showcasing emerging Animal Health and Nutrition companies, from China and across Asia-Pacific, that are activity seeking financial investment or strategic partnership conversations with large corporate firms.
Our plenary sessions provide guidance on veterinary market trends and animal health industry dynamics in China & A-PAC, insight on how emerging companies are using new innovations to prevent disease and market analysis on the M&A activity across the animal health and nutrition markets in Asia.
Testimonials
"This is a unique event for our animal health industry. It brings local and international players together, and provides an excellent platform to build business partnerships.”
Tony Zilong Tan, Z-Link Biotech Co. Ltd.
“This meeting is a very exciting one – it’s a platform to meet everyone from Chinese animal health and International animal health companies, and to introduce them to one-another. This way you save time and it gives you more chance to keep ahead of the innovations.”
Tingwu Xue, China Animal Husbandry Group (CAHG)
“I think this is a great meeting for companies to come together and find out what the common challenges are and how they can work together. I’m really impressed!"
Jishu Shi, U.S.-China Centre for Animal Health
"Everybody’s here, you can have many meetings in one spot, learn how to work together, increase your network and search for ideas.”
Joachim Hasenmaier, Boehringer-Ingelheim
Highlights from the Series
Innovation Showcase
Our Selection Committee will select twelve Emerging/ Start-up companies from the list of applications to present on-site to the audience of strategic partners from APAC, China and around the world. These presentations will showcase the innovation and opportunity that the emerging companies bring to their various markets.
Submissions will be accepted from companies in the following categories: Nutrition and Health for Livestock or Companion Animals. They should be early to mid-stage companies that are actively looking for financial investment or strategic partnerships, and can range from pre-revenue companies all the way up to larger entities that have annual revenues of up to $10 million USD.
Thank you to everyone that entered!
We're excited to announce the Finalists. Results announced in the Resources section below (click here to be redirected)
Please note: All companies that are selected to present as part of the Showcase will receive a 2nd ticket free of charge for a co-presenter to attend the event.
University Pavilion
Brand new for 2018 is the University Pavilion open networking and poster session.
The top veterinary Universities in Asia Pacific will present their facilities, research and technologies for potential partnering opportunities all day on October 24 & 25.
If you're an academic institution don't miss out on showcasing your research - email Calan for more information: [email protected]
Who You Will Meet
Attendees will represent the following key stakeholder groups in the Animal Health market
- Heads of Business Development, Animal Health, R&D from Multinational Pharmaceutical Companies
- CEOs, CSOs and Heads of Business Development from Emerging Animal Health Companies
- CEOs, Heads of Business Development, Product Discovery and Marketing from Incubators/ Accelerators, Contract Research Orgs, Consultants, Lawyers and other Service Providers
…all of the above with an interest in Livestock, Aquaculture and the Companion Animal markets
Attendees expected from the following key stakeholder groups and organizations
New for 2018
Alongside the already popular Animal Health conference track, this year's event brings you:
Nutrition
- Dedicated animal nutrition track covering: Medicated feed additives, oral vaccines and the animal microbiome; The innovation trends impacting the gut health of companion animals, aquaculture and livestock; The unique regulatory requirements for feed additives in China.
- An Innovation Showcase highlighting the four most exciting partnering and investment opportunities for animal nutrition in China
Academia
- University Pavilion showcasing research from the top veterinary universities in China and Asia- Pacific
- Pre-schedule private meetings to facilitate business-to-academia partnership discussions
- Roundtable discussion on partnering strategies between business and academia
Benefits of Attending
- Identify your next stategic partner in animal health and nutrition.
- Collaborate and make deals with senior-level animal health executives and financial investors.
- Discover the latest advancements in innovation and R&D.
- Gain the investment or M&A interest your business needs to succeed in the marketplace.
The Agenda
You can download our latest agenda here.
Simply fill in this form and we'll send you a PDF version immediately. We need some information to know where to send the file and how to address our email to you.
New for 2018 the event has expanded to cover three key areas: Health, Nutrition and Academia. Sessions include:
- INNOVATION: Health and nutrition start-ups from China and A-PAC pitch their novel technologies, looking for partnership opportunities in 3 Showcases
- HEALTH TRACK: Back for its 3rd year, covering animal health M&A, product regulation, drivers of the Chinese pet industry and implications of emerging diseases in A-PAC
- NUTRITION TRACK: Dedicated animal nutrition track covering oral vaccines, innovation in gut health, and regulatory requirements for feed additives in China
- ACADEMIC TRACK: A university pavilion showcasing research from the top 15 veterinary universities in China and A-PAC
Download the agenda to learn more...
Download the 2018 Agenda
NEW FOR 2018: WORKSHOPS
WORKSHOP 1: Preventive Health and Wellbeing in Swine
This is an exclusive opportunity for innovative companies, Key Opinion Leaders and researchers in China and the APAC region to partner with leading global animal health company, Elanco.
Elanco Animal Health are world leaders in prevention through their portfolio of products to prevent and treat parasites and infectious diseases in swine and have one of the highest levels of investment in the creation of future solutions in these areas.
Attendees to this workshop should be experts in the areas of prevention and wellbeing in swine and should contribute to a state-of-the-art debate as to actionable solutions to advance these areas. They can expect to work together with Elanco Animal Health senior executives in the early assessment of high potential opportunities and action plans around collaboration and strategic partnerships.
Attendance for maximum 30 APAC start-up companies or academic researchers only. Individuals must apply for a complimentary pass online.
----------
WORKSHOP 2: Partnering to Transform an Idea into a Final Product: What a leading Animal Health company can bring to a Start-up
- A vast regulatory world outside of China.... with rules, traditions, complexities
- Great discoveries need suitable marketing formulations
- A misled IP review, a potential nightmare even for the best inventions
- Quality and Good Practices... Expanding into other territories for global sales
Attendance for maximum 30 APAC start-up companies or academic researchers only. Individuals must apply for a complimentary pass online.
Applications for both workshops are now closed
Speakers
Dr. Cai XuePeng
Dr. Cai Xuepeng has been President of Chinese Veterinary Association (CVMA) since February 2017. In his professional career, he held a number of prominent leadership roles in government institutions related to control of animal diseases and animal health, including as former Director of Lanzhou Veterinary Research Institute, Director of the Chinese Center for Animal Disease Control and Prevention (CCDC), Director of China Institute of Veterinary Drug Control (IVDC), and Director of Veterinary Drug Evaluation Committee, the Ministry of Agriculture. Dr. Cai received his degree in Veterinary Medicine from Heilongjiang College of Animal Husbandry and Veterinary Medicine, his Master’s Degree in Parasitology from Chinese Academy of Agricultural Sciences, and his PhD in Veterinary Medicine from Nanjing Agricultural University.
才学鹏
中国兽药协会会长
才学鹏先生自2017年2月起担任中国兽药协会会长一职。在他的职业生涯中，他先后担任过与动物疾病防治有关的政府和科研机构要职，包括兰州兽医研究所所长、中国动物疫病预防控制中心主任、中国兽医药品监察所所长和农业部兽药评审中心主任。他本科毕业于黑龙江畜牧兽医学校兽医学专业；在中国农业科学院研究生院兽医寄生虫学与寄生虫病学专业取得硕士学位；在南京农业大学获得了兽医博士学位。
Dr. Isabelle Dieuzy-Labaye
Dr. Isabelle Dieuzy-Labaye is Senior Advisor, Public-Private Partnerships, at the World Organisation for Animal Health (OIE), an intergovernmental organisation with 182 Member Countries, headquartered in Paris.
She has over 20 years of experience in the animal health market and in the life sciences and innovation sectors, working in the US and now in Europe. Prior to her appointment at the OIE in November 2016, Isabelle was the Director, Strategic Alliances, for Europe, Africa and the Middle East at Zoetis, the leading animal health company worldwide. In this role, she started and led multiple open innovation initiatives through collaborations with various partners at the public-private interface, including large academic research entities, government institutions, startup companies, foundations and charities, driving scientific and developmental projects towards outcome and impact.
Isabelle is a board member at Ecole Nationale Vétérinaire d’Alfort and at the Moredun Research Institute in Scotland. She is also a member of the Strategic Committee of Agreenium, the French consortium of agronomical education and research institutes, and of the Technical and Scientific Committee of GALVmed, a UK-based NGO which makes livestock vaccines, medicines and diagnostics accessible and affordable to developing countries. She recently joined the Scientific Council of the Animal Health Department of INRA.
Isabelle holds a DVM from Ecole Nationale Vétérinaire d’Alfort and obtained her MBA at INSEAD.
Clinton Lewis
Clint Lewis is executive vice president and president of International Operations at Zoetis. In this role, he oversees the management of the livestock and companion animal business markets outside the United States.
Mr. Lewis previously served as president, U.S. Operations at Zoetis and in the Pfizer Animal Health organization. He joined Pfizer Animal Health in 2007.
Mr. Lewis joined Pfizer in 1988 as a sales representative in Long Island, N.Y., and has held positions of increasing responsibility in several areas across various commercial operations dedicated to human health prior to joining animal health, including vice president and general manager of Pfizer’s U.S. Anti-Infectives/HIV business unit.
In 2011, Mr. Lewis was elected chairman of the Animal Health Institute (AHI) for the 2011-12 term. A member of AHI since 2007, Mr. Lewis previously served as AHI vice chair for the 2009-2010 term. AHI is the trade association for the animal health industry in the U.S. advocating on various issues important to the industry, including efficient and effective regulatory and approval processes by the U.S. Department of Agriculture (USDA), the Food and Drug Administration (FDA), and the Environmental Protection Agency (EPA).
Mr. Lewis holds a bachelor’s degree in biology from Fairfield University and a Master of Business Administration in marketing from Fairleigh Dickinson University.
Sébastien Huron
Sébastien Huron, 46, DVM, started his career in 1994 in Brazil in the Hoechst-Roussel group where he rapidly rose to become the Marketing director of the animal health division. After Intervet acquired this division (Akzo Nobel group), which was then integrated into the Merck Group, Sébastien Huron pursued his career in 2000 in the United States as Market Development director, and then as director of the Pet division. After rejoining the Virbac group in 2006 as the general manager of the Spanish subsidiary, he then became the director of the European region in 2008, and then head of Global Business Operations in 2013. He has been part of the Virbac executive board since December 2012.
Ruiai Chen
Dr. Ruiai Chen received her Ph.D. in Microbiology from the China Agricultural University. Currently she is a professor and Ph.D. advisor at the College of Veterinary Medicines, South China Agricultural University.
Dr. Chen is President of Guangdong Wens Dahuanong Biotechnology Co., Ltd. (DHN), and Vice-Chairman of the China Veterinary Drug Association (CVDA). She is one of the most influential leaders in the Chinese animal health arena and, as a result, she is entitled to special allowances provided by the Chinese State Council, an honor for outstanding scientists in China. Dr. Chen is a well-known expert in the prevention and control of animal diseases, and vaccine research.
She possesses 41 patents and 22 new veterinary drug certificates. Dr. Chen has received 14 technical awards at the provincial and national levels, such as first prize for the Guangdong Provincial Science and Technology Award and the China Outstanding Patent. Her achievements include the development and industrialization of avian influenza vaccines, PRRS vaccines and coccidiosis vaccines. These vaccines are now making great contributions to disease control in China, Southeast Asia (e.g., Indonesia), and Middle East countries. Dr. Chen is also director of the Enterprise Key Laboratory of MOA for Animal Disease Prevention and Control, Biotechnology and Biological Product R&D. She has contributed greatly to commercialization of technology for animal vaccine and pharmaceutical products.
Dr. Jihong Kim
Dr. Jihong Kim is the chairman of Green Cross Veterinary Products Co., Ltd.. a leading animal health company in South Korea established since 1973. In his role, he is leading the international partnership and globalization initiatives.
Dr. Kim holds MBA from Harvard Business School and PhD from University of California, Berkeley. He was a professor and an associate dean of Korea Development Institute School of Public Policy and Management. He received Official Commendation from Vice Prime Minister, Ministry of Economy and was an Advisory Board Member of Ministry of Finance and Economy, South Korea.
Scott Holmstrom
Currently, Dr. Holmstrom leads Elanco’s global food animal product development efforts for pharmaceutical and vaccine products for swine, poultry, beef, dairy, and aqua. In this role, he provides the strategic direction for the global development of products through external and internal coordination, governance, and resourcing.
Scott D. Holmstrom, Ph.D., received his doctorate in analytical chemistry from Miami University in 2000 and joined Elanco Animal Health the same year.
As a research scientist from 2000 through 2006, Dr. Holmstrom has provided chemistry and drug disposition expertise and significant contributions toward the development and commercialization of drug products for Elanco, including global approvals for Comfortis and Trifexis. His work has influenced numerous companion animal and food animal programs targeting ectoparasites, endoparasites, coccidiosis, ketosis, and feed efficiency. In these assignments, Dr. Holmstrom has developed and validated analytical and bioanalytical methods, and led technical teams to elucidate the metabolism, pharmacokinetics, and pharmacodynamics of existing products and new compounds.
From 2006 - 2012, Dr. Holmstrom led cross-functional product development teams to obtain global registration of new chemical entities for companion animals, targeting parasiticides. Additionally, from 2011 – 2013, he served to integrate the Jannsen Animal Health research and development efforts with those of Elanco.
From 2013-2016, Dr. Holmstrom led global regulatory affairs for Elanco. In this role, he was responsible for shaping the regulatory landscape to enable outcomes for Elanco, their customers, as well as ensure that Elanco deliverables are completed in accordance with appropriate regulations and commitments to global regulatory authorities. This position provides direction for activities according to the company objectives and plays a key role in the development of short term and long-term company strategy.
In 2016, Scott led Elanco’s efforts for development and execution on late stage external innovation strategies. In this role, he developed specific strategies and execution plans to collaborate with external companies to commercialize products will support near and mid-term growth objectives for Elanco.
Alex T. Zhang
More than 20 years' professional experiences in equity investment, management consulting and founder of three successful technology companies
Dr. Hu Hongbin
Occupation:
The president of Beijing E-feed & E-vet (EFEV) Co.Ltd
The Director of Veterinary Drugs Distribution and Service working committee, CVDA
The Compere of International Animal Health Forum, CVDA (China Veterinary Drugs Association)
The Chairman of Beijing Veterinary Drugs Association
The Vice Chairman of China Feed Economy Committee
Education:
1985-1990 Veterinary College, China Agriculture University (Bachelor of Veterinary Science)
2003-2006 Animal Medical College, China Agriculture University (Master of Veterinary Science)
Occupational History:
1990-1991 Veterinarian, Beijing Dongsheng Agriculture & Animal Husbandry Co.Ltd
1992-1994 Sales Consultant/Mainland of China, Veterinary Medicine Division of MSD (Hong Kong) Co.Ltd
1995-1999 Marketing & Sales Director/Great China Region, Animal Health Division of Hoechst GmbH
2000-2001 Sales Manager/China, Intervet Animal health Co.Ltd
2002- President of Beijing E-feed & E-vet (EFEV) Co.Ltd
Dr Xu Bing
Education:
PHD, veterinarian, China Agricultural University
Main Working experience:
2010-present, Chairman, Beijing GoldenVet Biotech Co., Ltd.
2002-2010, Chief Representative (China), Virbac
1999-2002, Marketing manager (China), Schering-Plough Animal health.
1997-1999, Regional Sales Manager, Roche (China) Investment Co., Ltd.
1995-1997, Sales Rep, Conti (Beijing) Feed Additives Ltd.
Emma Davies
Emma Davies advises international clients on M&A and joint ventures in the Asia region, with particular focus on mainland China.
Emma heads up the firm's Corporate practice in mainland China and its Healthcare and Life Sciences Group in Asia.
Emma founded the China competition practice of Clifford Chance and continues to advise clients on the firm's more contentious merger clearances in the market.
Dr. Tony Zi Long Tan
Dr. Tan has over 30 years experience in the field of animal health across a range of animal species. He has had management roles in R&D, regulatory affairs, manufacturing, marketing, sales, and business development. Dr. Tan has extensive international business experience and has worked in the USA, Europe and Asia (particularly in China). Dr. Tan is the founder and Managing Partner of Z-Link Biotech Co. Ltd., a service and support company that helps animal health organizations to achieve their growth and stakeholder value in the emerging market.
Dr. Tan received his veterinary degree from Foshan Veterinary College in China, his Master’s Degree in Animal Science from Alcorn State University, and his Ph.D. in Microbiology from Kansas State University. During his earlier research career, Dr. Tan helped develop several vaccines for cattle, dogs, and poultry. He has published over 50 scientific publications and research reports.
Dr. Tan served Intervet-Schering Plough (now Merck/MSD Animal Health) for over 15 years in different positions, including R&D Group Leader, Project Manager Vaccine Manufacturing, Technical Marketing Manager Aquatic Animals, and Business Unit Director Companion Animals China.
From 2009 to March 2016, Dr. Tan was Group Director of Business Development and Global Alliances for the Asia-Pacific Region of Zoetis (formerly Pfizer Animal Health). He successfully completed several large M&A transactions (total transaction value in excess of US$100 million) and a number of technology licensing deals. These include the first antitrust divesture project in China, the company’s first joint venture project for vaccine manufacturing, and divesture of a pharmaceutical manufacturing plant in Taiwan.
Dr. Tan is an Advisor to the China Global Investment & Trading Alliance (CGITA), an organization that promotes international business between China and other countries.
谭博士在动物保健领域从业超过30年，涉及各种动物品种和岗位部门，包括研发、产品注册、生产、市场、销售以及业务拓展。谭博士拥有丰富的国际工作经验，曾在美国、欧洲和亚洲（特别是中国）国家工作。谭博士是易联生物科技有限公司的创始人。易联生物科技是一家咨询公司帮助动保公司在新兴市场服的发展。
谭博士毕业于佛山兽医专科学校、从阿尔肯州立大学取得了动物科学的硕士学位、从堪萨斯州立大学取得了微生物学的博士学位。在他的研究生涯中，为牛、狗以及家禽类开发了数种疫苗，并且发表了超过50篇科学论文和研究报告。
谭博士在英特威/默沙东动物保健公司工作了超过15年，期间担任了不同职位，包括研发部主管、疫苗制造项目经理、水生动物的技术市场经理以及中国伴侣动物的事业部总监。
从2009年到2016年，谭博士在硕腾（原名辉瑞）担任业务拓展部门和国际联盟亚太地区高级总监。他成功地完成了数项重大企业并购交易（总交易额超过一亿美元）和若干技术转让项目。其中包括中国第一个反垄断剥离项目，辉瑞在中国的第一个合资企业和出售台湾的一家医药制造工厂。
此外，谭博士还是中国际投资和贸易联盟(CGITA)的顾问。CGITA是一个致力于促进中国和其他国家之间国际商务的组织。
Dr. Zhao Yarong
Professor, Yarong ZHAO received Ph.D. in Veterinary Parasitology from China Agricultural University in 1993. With his cutting-edge researches in cryptosporidiosis, he received the First Grade Science & Technology Award from the Chinese Ministry of Agriculture in 1993.
From 1993 to 1998, he worked as National Technical Manager in Bayer Animal Health China. Later then in Fort Dodge Animal Health and Schering-Plough China as Regulatory and Technical Manager.
In 2003, he was appointed as General Manager of the Animal Medicine Research Center of the Dabeinong (DBN) Group, an innovative R&D center which focusing on animal infection disease diagnosis, animal biologic development and technology transfer. He has published over 50 scientific papers. Under his leadership, the Center has obtained Six National New Veterinary Drug Certificates and complete a number of technology transfer to other animal health companies with a total transaction value of approximately 350 million(RMB); Inactivated porcine circovirus type 2 (PCV2) vaccines, won the First Class State Science & Technology Progress Award in 2012.
Mr. Miles Yao
Miles Yao had studied virology and he holds a Master Degree in Preventive Veterinary Medicine from China Agriculture University, he also holds Master Degrees in Agricultural Economics from Purdue University, and an MBA from Indiana University-Kelley School of Business. Prior to this, he studied in Huazhong Agricultural University and earned an Animal Science Degree.
Miles Yao founded MarketVisor AgConsulting in 2015, and since then serves as its Managing Director, responsible for market development and entry strategies, as well as day-to-day engagement with commercial, government, and trade association contacts for clients. He and his team at MarketVisor are business partners for some leading trade associations and international and domestic animal health companies.
In 2018, Miles founded BioVantage with other investing partners, committing to be a Contract Research Organization in animal health sector.
Prior to being an entrepreneur, Miles has worked in leadership roles overseeing commercial and regulatory affairs with a Hong Kong based agribusiness company. He has lead China market entry strategies for agricultural products and animal health products from clients in the US, Mexico and EU. In these roles, Miles has ensured the market access, developed and managed distribution networks, key in-market client relationships and day-to day business activity.
From 2007-2013, Miles also worked in the Beijing USDA-APHIS office promoting safe and sustainable agriculture trade in China, Hong Kong, Macau and Mongolia. His primary focuses were technical and trade consultations between Government and industry, trade barrier reduction and negotiation, and agriculture policy analysis and execution. Miles had worked with Boehringer Ingelheim Animal Health for two years during 2005-2007, while at BI, his primary focus was swine sector. He also worked in poultry sector with Beijing Efficacy Biotech Co. as a Technical Manager for some time.
Contact:
Randolph Seidler
Mark J. Micallef
Mr. Rob Kelly
Nicolas Besse
Kyoon Andrew Kim
Norman Lee
Norman Lee, Ph.D., Professor and founder of Tianjin Ringpu Bio-Technology Co. Ltd., Director of the MOA’s Key Laboratory for Veterinary Drug Innovation, Chairman of the National Veterinary Drug Industry Strategic Alliance for Technology and Innovation, Vice-President of the Chinese Veterinary Association, President of the Tianjin Veterinary Medicine Association, post-graduate advisor at the Tianjin Agricultural University. Dr. Lee has led over 21 national, provincial, and municipal science and technology projects. He was recipient of the second prize of the National Science and Technology Progress Award and twice of the first prize of the Tianjin Science and Technology Progress Award.
In 1998, Dr. Lee established Ringpu(Tianjin)Bio-Pharmacy Co. Ltd. And Ringpu (Baoding) Biological Pharmaceutical Co., Ltd. He also acted as General Manager of both companies.
In 2004, he was in charge of the research project: “Genetically engineering recombinant chicken α- interferon”. The project received the first prize of the Tianjin City Technology Innovation Award.
In 2008, he led a management team to restructure the company and established Tianjin Ringpu Bio-Technology Co. Ltd. He was appointed Acting Chairman of the Board.
On 17th September 2010, Tianjin Ringpu Bio-Technology Co. Ltd. was officially listed on the Shenzhen Stock Exchange and Dr. Lee is Chairman of the Board,
In 2012, Dr. Lee was part of the research team: “Swine and poultry pathogenic bacteria resistance research and its application in development of a safe and effective new veterinary drug”. The project received the second prize of the National Science and Technology Progress Award.
Kristin Bloink
Kristin Bloink manages all internal discovery efforts and all external technology evaluations and subsequent portfolio entries for R&D. She has 26 years of accomplishments in human clinical trials, animal drug discovery and development, translational model development and execution, and human and veterinary clinical medical delivery in the private as well as the military sector. She joined Novartis Animal Health in 2007 and integrated into Elanco Animal Health in 2015.
Klaus Hellmann
Mark Engel
Carel du Marchie Sarvaas
Carel du Marchie Sarvaas has been working as a senior government affairs and communications advisor in Brussels and Washington DC for 20 years.
He will move to IFAH from EuropaBio, the Association of Biotechnology Industries, where he has been Director for Agricultural Biotechnology for some 4 years. Prior to EuropaBio, Carel worked at international consultancies and think tanks in Brussels and Washington DC, most often serving clients with science-based policy and communications challenges.
Carel is experienced in the interplay between regulatory, political and communications issues as they relate to science, innovation and policy. A Dutch national, he is married and has four children. He has lived in South Africa, Canada, Brussels, and Paris and holds degrees from the University of Leiden and Johns Hopkins Universi
Yuki Ujimasa
Prof. Seong Kyu Song
Dr. Johnny A. Jacobsen
Johnny was appointed to a new role with Argenta in early 2017 as Global Head of Customer Experience and subsequently promoted in 2018 to be the Global Head of Business Development. In this new role, Johnny is leading a team focused on client engagement and relationship management and he also is responsible for the development and execution of the strategic direction of Argenta’s global marketing, branding and communications.
Headline Partner
Elanco
Website: http://www.elanco.com
Elanco (NYSE: ELAN) is a global animal health company that develops products and knowledge services to prevent and treat disease in farm animals and pets in more than 90 countries. With a 65-year heritage, we rigorously innovate to improve the health of animals and benefit our customers, while fostering an inclusive, cause-driven culture for more than 5,800 employees. At Elanco, we’re driven by our vision of food and companionship enriching life - all to advance the health of animals, people and the planet. Learn more at www.elanco.com.
Associate Partners
Boehringer Ingelheim
Website: http://www.boehringer-ingelheim.com
Boehringer Ingelheim is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates presently with a total of some 50,000 employees worldwide. The focus of the family-owned company, founded in 1885, is on researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine. In 2015, Boehringer Ingelheim achieved net sales of about 14.8 billion euros. R&D expenditure corresponds to 20.3 per cent of net sales.
For more information, please visit www.Boehringer-Ingleheim.com
Virbac
Website: https://uk.virbac.com/
Founded in 1968 by a French veterinarian, Virbac is an independent pharmaceutical laboratory dedicated to animal health, since its beginning. Currently the world’s 7th largest animal health company, Virbac sells products in more than 100 countries, offering a comprehensive and practical range of products and services covering the majority of species and pathologies. Virbac innovation, based on both technological advances and listening to its customers, relies on reactive production facilities which meet the highest international quality standards. For nearly fifty years, these features have allowed the company to build a personalized relationship with veterinarians and farmers around the world.
Nippon Zenyaku Kogyo Co., LTD
Website: http://www.zenoaq.jp
ZENOAQ aims to create a shared and everlasting future for humans and animals. Amidst efforts to improve drug development, veterinary therapy and biotechnology, ZENOAQ strives to enhance the value of animals. The core activities in ZENOAQ are deeply connected with our customers, which in turn, affects their animals in many different ways. These connections form a network that is not just limited to Japan, but is something that will also reach across international borders, creating mutual benefit for both humans and animals in the future.
Zoetis
Website: http://www.zoetis.com
Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 65 years of experience in animal health, Zoetis discovers, develops, manufactures and commercializes medicines, vaccines and diagnostic products, which are complemented by biodevices, genetic tests and precision livestock farming. Zoetis serves veterinarians, livestock producers and people who raise and care for farm and companion animals with sales of its products in more than 100 countries. In 2019, the company generated annual revenue of $6.3 billion with approximately 10,600 employees.
For more information, visit www.zoetis.com.
Consulting Partner
Z-Link Biotech
Website: http://www.zlinkbiotech.com
Z-Link Biotech is a service and support company with a focus on animal health and animal biotechnology. Our key team members are based in China and the U.S.A. and have extensive expertise across various therapeutic areas throughout the product life-cycle, from product R&D to commercialization. We aim to provide quality tailor-made services to: 1) Chinese companies who are seeking advanced technology and export opportunities, and 2) International companies who want to enter the growing Chinese market and/or improve market penetration.
Event Partner
Argenta
Website: http://www.argentaglobal.com
Argenta Limited, founded in 2006, is the world’s only combined contract research organization (CRO) and contract manufacturing organization (CMO) specializing in animal health. With accredited operations and facilities across New Zealand, the United States and Scotland, Argenta is fully equipped to offer a full range of products and services - from access to innovative intellectual property, formulations research and development (R&D), analytical methods development, clinical trial management through to pilot- technical transfer and commercial-scale manufacturing - to the global animal health industry. Argenta’s 400+ global team develops and exports products and services to over 40 countries.
A privately-owned company headquartered in Auckland, New Zealand, Argenta brings innovation, R&D and manufacturing expertise together in one global company. This makes it ideally placed to accommodate unique product requirements no matter the scale or complexity. Argenta’s facilities in New Zealand, the United States (Iowa, Kansas and New Jersey) and Europe (Scotland) enable the achievement of significant efficiencies in product development and technology transfer, and to provide market intelligence and in-depth knowledge of market preferences in different countries as required.
Argenta is honoured to work with a vast range of clients globally - from small and medium-sized enterprises (SMEs) to some of the largest industry players. Argenta has the R&D capabilities and manufacturing scale to service the requirements of the largest multinationals, while, at the other end of the spectrum, Argenta works with startups and small companies with great ideas to help them find solutions and bring their ideas to fruition.
For more information, please visit www.argentaglobal.com.
Clinvet
Website: http://www.clinvet.com
Clinvet is a GCP/GLP accredited Contract Research Organisation (CRO) established in 1999 and specialises in the conduct of laboratory and field-based efficacy, safety and metabolism trials for veterinary health products.
Since inception, Clinvet has conducted more than 1300 studies aiding in the discovery, development and registration of veterinary products worldwide.
Services offered by Clinvet
Laboratory in vitro and in vivo efficacy studies as well as safety and metabolism studies for animal medicine. We maintain an extensive bank of parasites (helminths and arthropods) originating from the US, EU and Africa for use in challenges on companion and production animals. Test animals frequently used include rats, rabbits, cats, dogs, goats, sheep, cattle and horses. We offer the following studies:
- Glass vial contact assay
- Artificial membrane feeding assay
- Proof of concept efficacy
- Dose determination and confirmation
- Parasite challenge efficacy
- Bioequivalence
- Pharmacokinetics
- Residue depletion
- Target animal safety
Clinical trial conduct as well as the following support services for animal clinical field and laboratory studies:
- Project management, monitoring and quality assurance
- Protocol, report writing and case report form (CRF) design
- Electronic database, design and validation (EDC/Paper)
- Data management, biostatistics and statistical programming
- Serological (IFA and ELISA) and molecular (qPCR and PCR) diagnostic testing
- Specialised molecular assay development
- Animal genetic profiling, parentage and mutation screening
- Genomic analysis of parasites
For more information, visit www.clinvet.com
The Department for International Trade (DIT)
Website: https://www.great.gov.uk/
The Department for International Trade (DIT) helps businesses export and grow into global markets. We also help overseas companies locate and grow in the UK - our services are provided in over 100 markets throughout the world.
We secure UK and global prosperity by promoting and financing international trade and investment, and championing free trade.
We are an international economic department, responsible for:
- bringing together policy, promotion and financial expertise to break down barriers to trade and investment, and help businesses succeed
- delivering a new trade policy framework for the UK as we leave the EU
- promoting British trade and investment across the world
- building the global appetite for British goods and services
IDT Biologika
Website: https://idt-biologika.com/en/
IDT Biologika is an innovative, privately-held life science company with 95 years of history and expertise in research, development and manufacturing of biologics for the global protection of human and animal health. Headquartered in Dessau-Rosslau, Germany, the company also holds animal health vaccine dedicated R&D and Manufacturing locations in Greifswald - district Riems and Cambridge, Canada. In Denmark, the Netherlands, France, Spain and Canada, IDT's Animal Health Business Unit operates through its own subsidiaries. In its recently acquired U.S. manufacturing facility in Rockville, MD, IDT Biologika Corporation, a subsidiary of IDT Biologika GmbH, primarily works on vaccine development for clinical phase I and II projects and provides early development capabilities for the human vaccine market. In the 2015 financial year, IDT Biologika achieved sales of approximately €200 million with its animal health, vaccines, and pharmaceutical business segments, an approximately 17 percent increase in business compared to the previous year. IDT Biologika currently has some 1,500 employees. IDT Biologika is a company of the family-owned Klocke Holding. Klocke Holding companies specialize in contract manufacturing and packaging of pharmaceuticals, vaccines, and cosmetic products. More information can be found at www.idt-animal-health.com
Klifovet
Website: http://www.klifovet.com
KLIFOVET provides high quality services for the animal health and animal nutrition industry regarding the registration and marketing of all kind of veterinary products. We support ambitious young biotech and veterinary pharma companies on their way to the top by providing full business and product development management, regulatory affairs consultancy including dossier writing, compilation and submission, and full CRO services for safety and efficacy studies. We are proud on 18 years of experience, well organized logistics, a highly motivated team, and a comprehensive net of co-operators and skilled investigators throughout Europe, North America and the world. We handle large multinational projects as professionally as national ones, complying to national, EMA, EFSA or FDA standards.
Tianjin Ringpu Bio-techenology Co.,Ltd.
Website: http://www.ringpu.com/en
Based on high-end genetic engineering, cell engineering, fermentation engineering and other technologies, Ringpu Bio-product industry has developed and produced bio-pharmaceutical products for the prevention, treatment and diagnosis of poultry, livestock, dairy cows and pet diseases,including inactivated vaccines,live Vaccine, diagnostic reagent, genetic engineering vaccine, synthetic peptide vaccine, animal antibody, etc.
Ringpu is committed to the continuous development and production of high quality and high value-added products. At present, it has more than 280 kinds of animal products for poultry, livestock, pets and aquatic, including nearly 170 kinds of chemical drugs, 50 kinds of biological products and 30 kinds of feed additives and more than 30 plant extracts. Our products are based on the highest ethical standards, our management is devoted to honesty and creditability, product quality is one of our ultimate goals. Ringpu keeps faithful quality promises, insisting on that the inner control criteria must be 10% higher than national standards - product quality spot check qualified rate is continuously 11 years in the forefront of the industry.
Guangdong Wens Dahuanong Biotechnology Co., Ltd
Website: http://www.gddhn.com
Guangdong Wens Dahuanong Biotechnology Co., Ltd. is a high-tech biotechnological enterprise that integrates the main business of biological products, pharmaceutical preparation, feed additives and new business of marine industry and aquatic medicines.
As a key member of the Chinese animal husbandry sector, our company has been playing an important role in animal disease control at domestic and overseas, especially in Highly Pathogenic Avian Influenza (AI) and Porcine Reproductive and Respiratory Syndrome (PRRS) control, and has been well received by governmental departments, veterinarian experts and animal husbandry enterprises.
Our company is constantly completing our product list, with various high-technology vaccines as leading products. We are expanding into the waterfowl, aquatic and pet area, emphasize in develop new-type veterinary biological products, natural additive, and Chinese herbal veterinary medicine. We are also extending to relevant chain industries such us egg products, immunization equipment and so on. Our company is also actively importing and exporting related products, expanding the network of sales and service. We provide full service for customers including but not limited to animal illness diagnoses and related training. Hence contributes to food safety, technical progress and healthy development of the animal husbandry industry.
Reviewing the past and looking into the future, we are convinced that under the leadership of company leaders our company will make continuous efforts to sharpen its core competitiveness, as well as to attain the goal of establishing itself as a world class biotechnology enterprise!
Media Partners
Animal Pharm | IHS Markit
Website: http://www.animalpharmnews.com
The only source of animal health and animal nutrition news and analysis you’ll ever need.
Animal Pharm gathers intelligence from across the animal health and animal nutrition industries. It keeps you abreast of critical developments, emerging trends, and changes to the business, regulatory and competitive environment.
We have been providing animal health professionals worldwide with news, analysis and insight for over 30 years, and cover the food producing animal and companion animal sectors. With extensive information on animal health products including antiparasitics, vaccines, pharmaceuticals, feed, feed additives and equipment.
Features include:
Analysis of business and company news
Reporting on key players in the industry
Market developments and trends
Analysis of the latest global regulatory changes
News on product research and development
Expert opinion and analysis
ChemLinked | Food
Website: https://food.chemlinked.com
ChemLinked Food Portal was created by REACH24H Consulting Group to bring quality and dependable food regulatory information across Asian-Pacific region to global audience in the food industry.
eFeed Link
Website: http://www.efeedlink.com
MAHNIA
Website: http://www.mahnia.com/aboutus.htm
Malaysian Animal Health and Nutrition Industries Association
Learn more about us on our website
Pig333
Website: http://www.pig333.com
Pig333.com is a community website, which covers the entire swine sector from "pig to pork". With the collaboration of international specialists, we generate our own content from which users can debate and share ideas. We have nearly eigtheen years experience generating independent online content for the swine sector.
What does 333 mean? Those familiar with pig production will know that the gestation of the sow is approximately 3 months, 3 weeks and 3 days long, so it is a key number!
Watt Global Media
Website: http://www.wattglobalmedia.com/
As an industry innovator, WATT Global Media has connected buyers and sellers in the poultry, animal feed and pet food industries through its media channels for 100 years.
Become a Sponsor
Kisaco Research provides the much-needed platform on which industry executives can network, connect and learn from each other as well as meet potential industry partners.
Far from the typical ‘meet-and-greet’ exhibition experience, you – as a sponsor or exhibitor – will be positioned as a partner of the event with a focus on the benefits of your product and brand, rather than just a name on an exhibition list.
With our extensive marketing experience and strategy, your partnership with Kisaco Research will grant you a sponsorship package that is an extension and enhancement of your current marketing and branding efforts. We value your ROI and will work with you directly on your specific goals and targets – that’s why we take special care in finding the most relevant end-users to attend, so that your financial and resource investment is smartly allocated.
Find out more by calling us at +44 (0)20 3696 2920 or email us at [email protected].
Register
Sending Your Team? Group Discounts Available!
Applicable for Primary Market, Service Provider and Industry Rates Only. Not available for Academic or ‘Start-Up’ rates
Book a Team of 3+ - Save an Additional 10% Off
Book a Team of 5+ - Save an Additional 15% Off
If you would like to register a team of 3 or more, please email [email protected] for your discount coupon code before registering. PLEASE NOTE: Discounts cannot be combined with Early Bird Pricing or any other discount or offer. If you have any questions about your registration, please call us on +44 (0)20 3696 2920
Venue
Sheraton Hong Kong Hotel & Towers, 20 Nathan Road, Kowloon, Hong Kong
Sheraton Hong Kong Hotel & Towers
20 Nathan Road
Kowloon
Hong Kong Special Administrative Region
Hong Kong
Phone: + (852) 2369 1111
Website: click here
Accommodation
We have arranged reduced rates at the conference hotel for event attendees. You can book these via our unique booking link here.
Please note that these discounted accommodation rates expire on October 10, 2018 and are subject to availability.
Global Advisory Board
WHO THEY ARE
Each of our Advisory Board members have been chosen based on numerous recommendations, their deep knowledge and Industry experience and ability to provide a clear vision, not just for their own organizations, but for the industry as a whole.
WHY THEY ARE HERE
Board members guide not just content, but also the underlying mission of the events to drive positive change.
Author:
Aaron Schacht
Mr. Aaron Schacht is currently the Vice President of Global Research and Development / Regulatory Affairs at Elanco Animal Health. Prior to this, Mr. Aaron Schacht held a role of Global Brand Development Leader – Pain in Lilly Biomedicines. He was the global leader for product development and commercialization activities for LY2951742 – Lilly’s novel CGRP neutralizing antibody – a new potential treatment for prevention of Migraine and Cluster Headache. In 2012, Schacht joined Lilly Biomedicines as Senior Advisor – Strategy & Business Development for Lilly BioMedicines. His responsibilities included oversight of Therapeutic Strategy development, R&D Portfolio Management, and Business Development for Lilly BioMedicines – Lilly’s largest business unit. Past roles included serving as Executive Director, Global External R&D, at Eli Lilly and Company, where he was responsible for implementation of strategies which aim to leverage novel approaches to external partnerships to augment Lilly’s access to pharmaceutical innovation as well as Executive Director of LRL (Lilly Research Labs) Strategy, Portfolio Management and Project Management where he was responsible for strategic planning, R&D portfolio and project management. Prior to these roles, he was Director, Innovation Center in the eLilly organization where he focused on the exploration, incubation and implementation of new business models and capabilities relevant to the strategic evolution of the pharmaceutical industry. In 2002, during a short leave from Lilly, Mr. Schacht was co-founder, President and CEO of Artesian Therapeutics, a Gaithersburg, MD cardiovascular drug discovery start-up. Mr. Schacht began his career at Lilly in 1990 as a medicinal chemist, and spent 5 years in the laboratory working to discover pharmaceuticals to treat cardiovascular disorders. Schacht studied Organic chemistry at the University of Illinois, receiving his Bachelors of Science degree in 1990.
Author:
Jishu Shi
Dr. Jishu Shi, Professor of Vaccine Immunology, is the director of U.S.-China Center for Animal Health at Kansas State University. Dr. Shi is devoted to advance veterinary education and industry standards in China and around the world. He was instrumental in establishing the Kansas State University and China Scholarship Council Joint Doctor of Veterinary Medicine (DVM) Program that will train 50 Chinese students in the next 10 years through American Veterinary Medical Association-accredited DVM programs in the U.S. For the first time in 63 years since 1950, students from China are being supported ($14 million for 50 students) by their home country to earn a DVM degree from the United States. As the Special Assistant to the Provost for China Affairs at Kansas State University, Dr. Shi worked with Chinese government and universities to set up a Confucius Institute at Kansas State University (CI-KSU) in 2015. CI-KSU is the 102rd CI in the U.S. and has a special focus on agriculture security, public health, and animal health.
Dr. Shi teaches veterinary physiology to the first year students at the College of Veterinary Medicine at Kansas State University. He is the author of more than 100 publications in refereed journals, conference proceedings and book chapters. Dr. Shi’s research programs focus on the development of vaccines for high consequence animal diseases such as classical swine fever (CSF) and porcine reproductive and respiratory syndrome (PRRS).
Having worked at Chinese Academy of Agricultural Sciences, Pfizer, and multiple academic institutions in the U.S. in the last three decades, Dr. Shi is a frequent consultant to animal health companies in the U.S., China, Japan, and Europe. In 2010, Dr. Shi founded VaxiAm Group, a global consulting firm with offices in Beijing and Kansas that focus exclusively on the Chinese animal health market. VaxiAm Group builds bridges between research labs and commercial entities in the U.S. and China and transforms innovative ideas to successful products. In addition, VaxiAm Group provides following services to its clients: investment due diligence, market analysis, regulatory affairs consultation, product registration, and selection of business partners including sales agents, distributors, product co-developers, and manufacturers.
Please see following web links for additional information about Dr. Jishu Shi:
http://www.vaxiamgroup.com
http://www.vet.k-state.edu/international/USCCAH
http://www.vet.k-state.edu/depts/ap/faculty/shi.htm
Contact info: [email protected]; Tel: 785-477-6977
Author:
Alan Mackay
Alan has been a private equity investor for more than 25 years in roles including Senior Partner and Global Head of Healthcare at the private equity firm 3i Group plc. He was appointed to the board of 3i plc in 1993 and became CEO of 3i Nordic plc, based in Stockholm, upon the acquisition of Sweden's largest listed private equity company Atle AB in 2001. Alan has served on the boards of a number of healthcare companies, including most recently Phibro Animal Health Corporation which completed a successful initial public offering (IPO) in April 2014. Latterly he has been Managing Partner, CEO, and Chairman of the Investment Committee, of Hermes GPE, an active co-investor in private equity backed healthcare. Alan holds a Bachelor's degree in Law, an MSc in Enterprise and is a graduate of the Advanced Management Programme at INSEAD. He is Chair of the BVCA for 2016 – 2017 and previously chaired its Responsible Investment Advisory Board.
Author:
Linda Rhodes
Dr. Rhodes has 28 years of accomplishments in human and animal drug discovery, development, biomedical research, and clinical veterinary medicine.
Dr. Rhodes was educated at the University of Pennsylvania School of Veterinary Medicine (VMD) and Cornell University (PhD). She has 28 years of accomplishments in human and animal drug discovery, development, biomedical research, and clinical veterinary medicine. She has an extensive background in physiology, veterinary medicine, and molecular biology. As a senior research fellow at Merck Research Laboratories for 10 years, she led pre-clinical biology evaluation of several marketed human drugs. Dr. Rhodes practiced clinical veterinary medicine for five years, with experience in both companion and farm animal practice. She worked for Merial Ltd. as director of development projects, leading project teams developing novel compounds for a variety of indications and headed new technology assessment, leading the evaluation of licensing opportunities. In April 2001, she formed AlcheraBio, a consulting, marketing, communications and contract research firm specializing in developing new drugs for animals, working with biotechnology and animal health companies, with clients in the US, European Union, Canada and Australia. AlcheraBio was acquired in 2008 by Argenta, and in 2011, Dr. Rhodes accepted a position as CEO of Aratana Therapeutics, a company developing innovative new medicines for dogs and cats, and subsequently, when the company became public (PETX) served as its Chief Scientific Officer. During her tenure, development was completed on three new pet therapeutics: two new molecules with novel mechanisms of actions were approved by the FDA, and a third drug had FDA registration completed and was approved in August, 2016. She is currently retired and an independent consultant. She is a member of the Board of Directors of ImmuCell (NASDAQ: ICCC) and the Alliance for Contraception in Dogs and Cats, serves on the Scientific Advisory Board of the Found Animals Foundation. She is an adjunct faculty member in the Graduate Animal Science program at Rutgers University.
Author:
Joachim Hasenmaier
Joachim Hasenmaier, born 1960 in Vaihingen/Enz, Germany, DVM., is Member of the Board of Managing Directors of C.H. Boehringer Sohn AG & Co. KG since October 1, 2012, responsible for the Corporate Board Division Consumer Health Care and Animal Health. His nationality is German.
He received a veterinary medical degree (DVM) in 1986 from Ludwig-Maximilians-University, Munich, where he entered into a microbiological research program until 1989 receiving his Doktor med. vet. (PhD) degree. He completed his education with a Master in Management from Kellogg Business School, Chicago, USA in 1991. Prior to joining BI he worked in various positions for various international companies in Germany, Japan, Mexico and Brazil.
In 2002 he joined Boehringer Ingeheim as Corporate Senior Vice President for Boehringer Ingelheim Animal Health. In 2011 he took over the regional responsibilty for Prescription Medicine in NECAR (UK/Ireland, Nordics, Benelux, Canada, Australia/New Zealand). He held this position until he became Member of the Board of Managing Directors at C.H. Boehringer Sohn AG & Co. KG in October 2012.
Author:
Clinton Lewis
Clint Lewis is executive vice president and president of International Operations at Zoetis. In this role, he oversees the management of the livestock and companion animal business markets outside the United States.
Mr. Lewis previously served as president, U.S. Operations at Zoetis and in the Pfizer Animal Health organization. He joined Pfizer Animal Health in 2007.
Mr. Lewis joined Pfizer in 1988 as a sales representative in Long Island, N.Y., and has held positions of increasing responsibility in several areas across various commercial operations dedicated to human health prior to joining animal health, including vice president and general manager of Pfizer’s U.S. Anti-Infectives/HIV business unit.
In 2011, Mr. Lewis was elected chairman of the Animal Health Institute (AHI) for the 2011-12 term. A member of AHI since 2007, Mr. Lewis previously served as AHI vice chair for the 2009-2010 term. AHI is the trade association for the animal health industry in the U.S. advocating on various issues important to the industry, including efficient and effective regulatory and approval processes by the U.S. Department of Agriculture (USDA), the Food and Drug Administration (FDA), and the Environmental Protection Agency (EPA).
Mr. Lewis holds a bachelor’s degree in biology from Fairfield University and a Master of Business Administration in marketing from Fairleigh Dickinson University.
Author:
Dirk Ehle
Dr. Dirk Ehle has been a member of the Bayer HealthCare Executive Committee and responsible for the Animal Health Division since May 1, 2012.
Dirk Ehle was born on May 26, 1969, in Cologne, Germany. He studied law at the universities of Freiburg, Aix-en-Provence (France), Wurzburg, and New York (USA).
After three years in law firms, Dirk Ehle started his career at Bayer in 2001 in the Law Department of Bayer HealthCare. In 2006, Ehle transferred to Bayer AG’s Corporate Office where he worked as Executive Assistant to the Chairman of the Board of Management. He was also in charge of Corporate Policy & Advocacy as of 2008. In 2010, Ehle was appointed Senior Bayer Representative for Central Eastern Europe and Bayer HealthCare Representative for Poland.
Dirk Ehle is married with three children.
Author:
Dr. James Lloyd
Education
- PhD, Agricultural Economics & Operations Research, Michigan State University, 1989
- DVM, Michigan State University, 1981
- BS, Fisheries & Wildlife, Michigan State University, 1978
Honors and Awards
- LGVMA Leadership Award, 2013
- President’s Honor Roll, Michigan Veterinary Medical Association, 2006, 2007, 2008, 2009, 2011
- Senior Fellow, Outreach and Engagement, Michigan State University, 2005-13
- Certificate of Appreciation, Assoc. of Vet. Practice Management Consultants and Advisors, 2004
- Norden Teacher of the Year Award Finalist, College of Veterinary Medicine, 2003
- Creativity in Teaching Award, Merck Agvet, 1995
- State Team Award, Milk Quality Assurance Program, Michigan State University Extension, 1993
- Commendation (for Extension activity), Michigan Cattlemen’s Association, 1992
- The Honor Society of Phi Kappa Phi, Michigan State University, inducted 1985
- Phi Zeta, Honorary Veterinary Society, Michigan State University, inducted 1981
- Butler Award, voted by peers as “most likely to succeed” in large animal veterinary medicine, 1981
- Honors College, Michigan State University, 1975 to 1977
Interests
Dr. Lloyd was leader of the National Commission on Veterinary Economic Issues working group on Enhancing the Skills, Knowledge, Aptitude, and Attitude of Veterinarians from 2000-2009. He also works as an organization development consultant, emphasizing strategic planning and leadership development with inclusion as a core element.
Author:
Sébastien Huron
Sébastien Huron, 46, DVM, started his career in 1994 in Brazil in the Hoechst-Roussel group where he rapidly rose to become the Marketing director of the animal health division. After Intervet acquired this division (Akzo Nobel group), which was then integrated into the Merck Group, Sébastien Huron pursued his career in 2000 in the United States as Market Development director, and then as director of the Pet division. After rejoining the Virbac group in 2006 as the general manager of the Spanish subsidiary, he then became the director of the European region in 2008, and then head of Global Business Operations in 2013. He has been part of the Virbac executive board since December 2012.
Selection Committee
Author:
Dr. Tony Zi Long Tan
Dr. Tan has over 30 years experience in the field of animal health across a range of animal species. He has had management roles in R&D, regulatory affairs, manufacturing, marketing, sales, and business development. Dr. Tan has extensive international business experience and has worked in the USA, Europe and Asia (particularly in China). Dr. Tan is the founder and Managing Partner of Z-Link Biotech Co. Ltd., a service and support company that helps animal health organizations to achieve their growth and stakeholder value in the emerging market.
Dr. Tan received his veterinary degree from Foshan Veterinary College in China, his Master’s Degree in Animal Science from Alcorn State University, and his Ph.D. in Microbiology from Kansas State University. During his earlier research career, Dr. Tan helped develop several vaccines for cattle, dogs, and poultry. He has published over 50 scientific publications and research reports.
Dr. Tan served Intervet-Schering Plough (now Merck/MSD Animal Health) for over 15 years in different positions, including R&D Group Leader, Project Manager Vaccine Manufacturing, Technical Marketing Manager Aquatic Animals, and Business Unit Director Companion Animals China.
From 2009 to March 2016, Dr. Tan was Group Director of Business Development and Global Alliances for the Asia-Pacific Region of Zoetis (formerly Pfizer Animal Health). He successfully completed several large M&A transactions (total transaction value in excess of US$100 million) and a number of technology licensing deals. These include the first antitrust divesture project in China, the company’s first joint venture project for vaccine manufacturing, and divesture of a pharmaceutical manufacturing plant in Taiwan.
Dr. Tan is an Advisor to the China Global Investment & Trading Alliance (CGITA), an organization that promotes international business between China and other countries.
谭博士在动物保健领域从业超过30年，涉及各种动物品种和岗位部门，包括研发、产品注册、生产、市场、销售以及业务拓展。谭博士拥有丰富的国际工作经验，曾在美国、欧洲和亚洲（特别是中国）国家工作。谭博士是易联生物科技有限公司的创始人。易联生物科技是一家咨询公司帮助动保公司在新兴市场服的发展。
谭博士毕业于佛山兽医专科学校、从阿尔肯州立大学取得了动物科学的硕士学位、从堪萨斯州立大学取得了微生物学的博士学位。在他的研究生涯中，为牛、狗以及家禽类开发了数种疫苗，并且发表了超过50篇科学论文和研究报告。
谭博士在英特威/默沙东动物保健公司工作了超过15年，期间担任了不同职位，包括研发部主管、疫苗制造项目经理、水生动物的技术市场经理以及中国伴侣动物的事业部总监。
从2009年到2016年，谭博士在硕腾（原名辉瑞）担任业务拓展部门和国际联盟亚太地区高级总监。他成功地完成了数项重大企业并购交易（总交易额超过一亿美元）和若干技术转让项目。其中包括中国第一个反垄断剥离项目，辉瑞在中国的第一个合资企业和出售台湾的一家医药制造工厂。
此外，谭博士还是中国际投资和贸易联盟(CGITA)的顾问。CGITA是一个致力于促进中国和其他国家之间国际商务的组织。
Author:
Dr. Hu Hongbin
Occupation:
The president of Beijing E-feed & E-vet (EFEV) Co.Ltd
The Director of Veterinary Drugs Distribution and Service working committee, CVDA
The Compere of International Animal Health Forum, CVDA (China Veterinary Drugs Association)
The Chairman of Beijing Veterinary Drugs Association
The Vice Chairman of China Feed Economy Committee
Education:
1985-1990 Veterinary College, China Agriculture University (Bachelor of Veterinary Science)
2003-2006 Animal Medical College, China Agriculture University (Master of Veterinary Science)
Occupational History:
1990-1991 Veterinarian, Beijing Dongsheng Agriculture & Animal Husbandry Co.Ltd
1992-1994 Sales Consultant/Mainland of China, Veterinary Medicine Division of MSD (Hong Kong) Co.Ltd
1995-1999 Marketing & Sales Director/Great China Region, Animal Health Division of Hoechst GmbH
2000-2001 Sales Manager/China, Intervet Animal health Co.Ltd
2002- President of Beijing E-feed & E-vet (EFEV) Co.Ltd
Author:
Mr. Miles Yao
Miles Yao had studied virology and he holds a Master Degree in Preventive Veterinary Medicine from China Agriculture University, he also holds Master Degrees in Agricultural Economics from Purdue University, and an MBA from Indiana University-Kelley School of Business. Prior to this, he studied in Huazhong Agricultural University and earned an Animal Science Degree.
Miles Yao founded MarketVisor AgConsulting in 2015, and since then serves as its Managing Director, responsible for market development and entry strategies, as well as day-to-day engagement with commercial, government, and trade association contacts for clients. He and his team at MarketVisor are business partners for some leading trade associations and international and domestic animal health companies.
In 2018, Miles founded BioVantage with other investing partners, committing to be a Contract Research Organization in animal health sector.
Prior to being an entrepreneur, Miles has worked in leadership roles overseeing commercial and regulatory affairs with a Hong Kong based agribusiness company. He has lead China market entry strategies for agricultural products and animal health products from clients in the US, Mexico and EU. In these roles, Miles has ensured the market access, developed and managed distribution networks, key in-market client relationships and day-to day business activity.
From 2007-2013, Miles also worked in the Beijing USDA-APHIS office promoting safe and sustainable agriculture trade in China, Hong Kong, Macau and Mongolia. His primary focuses were technical and trade consultations between Government and industry, trade barrier reduction and negotiation, and agriculture policy analysis and execution. Miles had worked with Boehringer Ingelheim Animal Health for two years during 2005-2007, while at BI, his primary focus was swine sector. He also worked in poultry sector with Beijing Efficacy Biotech Co. as a Technical Manager for some time.
Contact:
Author:
Mark Heffernan
Prior to joining Stonehaven Incubate, Dr Heffernan was the founding CEO and director at Nexvet Biopharma plc, a company pioneering the development of monoclonal antibodies in animal health. Since co-founding Nexvet in 2010, he raised more than US$80 million in capital, including the company’s NASDAQ public listing in 2015. Nexvet Biopharma was acquired by the world’s largest animal health company, Zoetis, in 2017.
Prior to Nexvet, he was also co-founder of an Irish biotechnology company, Opsona Therapeutics, focused on therapeutics for human inflammatory diseases where he raised US$50 million to commercialise research from Trinity College Dublin. Through his career, he has worked in research and business development in the USA, Asia Pacific and Europe.
About Kisaco Research
Kisaco Research produces, designs and hosts B2B industry conferences, exhibitions and communities – focused on a specialized selection of topic areas.
Meet industry peers that will help build a career-changing network for life.
Learn from the mistakes of your peers as much as their successes—ambitious industry stalwarts who are happy to share not just what has made them successful so far but also their plans for future proofing their companies.
Note down the inspired insight that will form the foundation for future strategies and roadmaps, both at our events and through our online communities.
Invest both in your company growth and your own personal development by signing up to one of our events and get started.